Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jan;67(1):156–158. doi: 10.1038/bjc.1993.27

Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study.

S Cascinu 1, A Fedeli 1, S L Fedeli 1, G Catalano 1
PMCID: PMC1968216  PMID: 8427776

Abstract

In 20 patients with cisplatin-associated anaemia (haemoglobin less than 90 gl-1), recombinant human erythropoietin was administered subcutaneously three times a week on an outpatient basis. The initial dose was 50 Units Kg-1 of body weight. If response was not achieved within 3 weeks, dose was increased to 75 Units Kg-1. Using the same criteria further escalation to 100 Units Kg-1 was performed. If there was no response erythropoietin was terminated. Fifteen patients obtained an increase in haemoglobin to above 100 gl-1 which was considered as a clinical response in this study, with a dose of 50 Units Kg-1; one patient needed an erythropoietin dose of 75 Units Kg-1 and one a dose of 100 Units Kg-1. Only three patients required haemotransfusions and were considered non responders. Haemoglobin increases occurred despite continuation of cisplatin chemotherapy. In conclusion subcutaneous low dose of erythropoietin seems to be effective and safe in the treatment of cisplatin-induced anaemia.

Full text

PDF
156

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexopoulos C. G., Chalevelakis G., Katsoulis C., Pallikaris G. Adverse effect of cis-diamminedichloroplatinum II (CDDP) on porphyrin metabolism in man. Cancer Chemother Pharmacol. 1986;17(2):165–170. doi: 10.1007/BF00306748. [DOI] [PubMed] [Google Scholar]
  2. Cazzola M., Ponchio L., Beguin Y., Rosti V., Bergamaschi G., Liberato N. L., Fregoni V., Nalli G., Barosi G., Ascari E. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood. 1992 Jan 1;79(1):29–37. [PubMed] [Google Scholar]
  3. Erslev A. J. Erythropoietin. N Engl J Med. 1991 May 9;324(19):1339–1344. doi: 10.1056/NEJM199105093241907. [DOI] [PubMed] [Google Scholar]
  4. Eschbach J. W., Kelly M. R., Haley N. R., Abels R. I., Adamson J. W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989 Jul 20;321(3):158–163. doi: 10.1056/NEJM198907203210305. [DOI] [PubMed] [Google Scholar]
  5. Ludwig H., Fritz E., Kotzmann H., Höcker P., Gisslinger H., Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990 Jun 14;322(24):1693–1699. doi: 10.1056/NEJM199006143222402. [DOI] [PubMed] [Google Scholar]
  6. Matsumoto T., Endoh K., Kamisango K., Akamatsu K., Koizumi K., Higuchi M., Imai N., Mitsui H., Kawaguchi T. Effect of recombinant human erythropoietin on anticancer drug-induced anaemia. Br J Haematol. 1990 Aug;75(4):463–468. doi: 10.1111/j.1365-2141.1990.tb07783.x. [DOI] [PubMed] [Google Scholar]
  7. McMahon F. G., Vargas R., Ryan M., Jain A. K., Abels R. I., Perry B., Smith I. L. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood. 1990 Nov 1;76(9):1718–1722. [PubMed] [Google Scholar]
  8. Miller C. B., Jones R. J., Piantadosi S., Abeloff M. D., Spivak J. L. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990 Jun 14;322(24):1689–1692. doi: 10.1056/NEJM199006143222401. [DOI] [PubMed] [Google Scholar]
  9. Miller C. B., Platanias L. C., Mills S. R., Zahurak M. L., Ratain M. J., Ettinger D. S., Jones R. J. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst. 1992 Jan 15;84(2):98–103. doi: 10.1093/jnci/84.2.98. [DOI] [PubMed] [Google Scholar]
  10. Oster W., Herrmann F., Gamm H., Zeile G., Lindemann A., Müller G., Brune T., Kraemer H. P., Mertelsmann R. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol. 1990 Jun;8(6):956–962. doi: 10.1200/JCO.1990.8.6.956. [DOI] [PubMed] [Google Scholar]
  11. Platanias L. C., Miller C. B., Mick R., Hart R. D., Ozer H., McEvilly J. M., Jones R. J., Ratain M. J. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991 Nov;9(11):2021–2026. doi: 10.1200/JCO.1991.9.11.2021. [DOI] [PubMed] [Google Scholar]
  12. Rossof A. H., Slayton R. E., Perlia C. P. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP). Cancer. 1972 Dec;30(6):1451–1456. doi: 10.1002/1097-0142(197212)30:6<1451::aid-cncr2820300606>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  13. Rothmann S. A., Paul P., Weick J. K., McIntyre W. R., Fantelli F. Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning. 1985 Nov;3(6):415–423. doi: 10.1002/stem.5530030607. [DOI] [PubMed] [Google Scholar]
  14. Von Hoff D. D., Schilsky R., Reichert C. M., Reddick R. L., Rozencweig M., Young R. C., Muggia F. M. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1527–1531. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES